News Image

Is NYSE:BMY a Good Fit for Dividend Investing?

By Mill Chart

Last update: Dec 14, 2023

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) has caught the attention of dividend investors as a stock worth considering. NYSE:BMY excels in profitability, solvency, and liquidity, all while providing a decent dividend. Let's delve into the details.

Analyzing Dividend Metrics

ChartMill assigns a proprietary Dividend Rating to each stock. The score is computed by evaluating various valuation aspects, like the yield, the history, the dividend growth and sustainability. NYSE:BMY was assigned a score of 7 for dividend:

  • With a Yearly Dividend Yield of 4.78%, BMY is a good candidate for dividend investing.
  • BMY's Dividend Yield is rather good when compared to the industry average which is at 4.60. BMY pays more dividend than 96.55% of the companies in the same industry.
  • BMY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.55.
  • On average, the dividend of BMY grows each year by 6.94%, which is quite nice.
  • BMY has been paying a dividend for at least 10 years, so it has a reliable track record.

What does the Health looks like for NYSE:BMY

To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NYSE:BMY has earned a 5 out of 10:

  • BMY has a Altman-Z score of 2.39. This is in the better half of the industry: BMY outperforms 71.92% of its industry peers.
  • The Debt to FCF ratio of BMY is 3.22, which is a good value as it means it would take BMY, 3.22 years of fcf income to pay off all of its debts.
  • BMY has a Debt to FCF ratio of 3.22. This is amongst the best in the industry. BMY outperforms 89.16% of its industry peers.

Profitability Assessment of NYSE:BMY

ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NYSE:BMY scores a 8 out of 10:

  • The Return On Assets of BMY (9.08%) is better than 92.61% of its industry peers.
  • The Return On Equity of BMY (28.57%) is better than 94.09% of its industry peers.
  • BMY has a Return On Invested Capital of 13.32%. This is amongst the best in the industry. BMY outperforms 90.64% of its industry peers.
  • The last Return On Invested Capital (13.32%) for BMY is above the 3 year average (9.56%), which is a sign of increasing profitability.
  • BMY has a Profit Margin of 18.44%. This is amongst the best in the industry. BMY outperforms 93.60% of its industry peers.
  • In the last couple of years the Profit Margin of BMY has grown nicely.
  • BMY's Operating Margin of 24.00% is amongst the best of the industry. BMY outperforms 92.12% of its industry peers.
  • BMY has a better Gross Margin (76.70%) than 82.76% of its industry peers.
  • BMY's Gross Margin has improved in the last couple of years.

Our Best Dividend screener lists more Best Dividend stocks and is updated daily.

Check the latest full fundamental report of BMY for a complete fundamental analysis.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

BRISTOL-MYERS SQUIBB CO

NYSE:BMY (4/26/2024, 7:04:00 PM)

After market: 44.88 +0.03 (+0.07%)

44.85

+0.15 (+0.34%)

BMY News

News Image2 days ago - Investor's Business DailyStock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review

Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.

News Image2 days ago - Bristol Myers SquibbCHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
News Image3 days ago - ChartmillWhich S&P500 stocks are moving on Thursday?

Get insights into the S&P500 index performance on Thursday. Explore the top gainers and losers within the S&P500 index in today's session.

News Image3 days ago - ChartmillThese S&P500 stocks are the most active in today's session

Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Thursday and discover the stocks that are dominating the trading activity and setting the pace for the market.

News Image3 days ago - Market News VideoNotable Thursday Option Activity: LUV, BMY, CARR
News Image3 days ago - ChartmillTop S&P500 movers in Thursday's session

Stay informed about the performance of the S&P500 index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.

News Image3 days ago - InvestorPlacePLTR Stock: Palantir Beefs Up Healthcare AI Work Through Parexel Deal

Palantir stock is slipping on Thursday even as PLTR traders learn of a new contract between the data company and Parexel.

News Image3 days ago - The Motley FoolWhy Bristol Myers Squibb Stock Is Sinking Today

Investors didn't like the biopharmaceutical company's updated guidance.

News Image3 days ago - InvestorPlaceBMY Stock Earnings: Bristol-Myers Squibb Beats EPS, Beats Revenue for Q1 2024

BMY stock results show that Bristol-Myers Squibb beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Image3 days ago - InvestorPlaceBristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts

Bristol-Myers Squibb layoffs will see the company reduce its headcount by 6% as part of an effort to reduce expenses in 2024.

News Image3 days ago - The Motley FoolBristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript

BMY earnings call for the period ending March 31, 2024.

News Image3 days ago - The Motley FoolIs Bristol Myers Squibb Stock a Millionaire Maker?

Bristol Myers Squibb faces some challenges, but there could be light at the end of the tunnel for long-term investors.

BMY Links
Follow us for more